Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interleukine-3: a multifunctional cytokine]

M Arock1

  • 1Faculté mixte de Médecine et de Pharmacie, Besançon.

Annales Pharmaceutiques Francaises
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The association of Greig syndrome and mastocytosis reveals the involvement of the hedgehog pathway in advanced mastocytosis.

Blood·2021
Same author

[The basophil: From control of immunity to control of leukemias].

Annales pharmaceutiques francaises·2021
Same author

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.

Leukemia·2017
Same author

Midostaurin: a magic bullet that blocks mast cell expansion and activation.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.

Leukemia·2017
Same author

Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia.

Leukemia·2015
Same journal

No evidence of significant natural environmental exposure to arsenic for Napoleon I on the island of Saint Helena (1815-1821).

Annales pharmaceutiques francaises·2026
Same journal

EFFECTS OF GLP-1 RECEPTOR AGONISTS ON PERIODONTAL TISSUE: AN INTERDISCIPLINARY EVIDENCE MAPPING - SCOPING REVIEW.

Annales pharmaceutiques francaises·2026
Same journal

Regulatory non-compliance of parallel imported medicines in Kenya and implications for public health: Evidence from Nairobi County.

Annales pharmaceutiques francaises·2026
Same journal

Prostaglandin analogues in cosmetic products formulated for eyelash lengthening.

Annales pharmaceutiques francaises·2026
Same journal

Mechanistic and thermodynamic evaluation of sodium citrate-mediated hydrotropism for the biopharmaceutical optimization of BCS Class II drug atorvastatin calcium.

Annales pharmaceutiques francaises·2026
Same journal

Future trends and the role of artificial intelligence in pharmaceutical project management.

Annales pharmaceutiques francaises·2026
See all related articles

Hematopoietic growth factors (HGF), like Interleukin-3 (IL-3), regulate blood cell development. While IL-3 alone shows limited therapeutic success, research explores combinations and fusion proteins for enhanced efficacy.

Area of Science:

  • Hematology
  • Immunology
  • Molecular Biology

Context:

  • Hematopoiesis is regulated by hematopoietic growth factors (HGF).
  • Interleukin-3 (IL-3) is a key HGF influencing early progenitor cells.
  • IL-3 has diverse roles in cell proliferation and immune responses.

Purpose:

  • To review the therapeutic potential of Interleukin-3 (IL-3).
  • To highlight limitations of IL-3 monotherapy.
  • To explore novel therapeutic strategies involving IL-3 combinations and fusion proteins.

Summary:

  • IL-3 exhibits proliferative effects on hematopoietic stem cells and regulatory functions in inflammation.
  • Therapeutic applications of IL-3 have been proposed for bone marrow abnormalities, chemotherapy, and transplantation.

Related Experiment Videos

  • Current evidence suggests IL-3 monotherapy yields disappointing results.

    • Impact:

    • Investigating IL-3 combinations (e.g., IL-3/GM-CSF, IL-3/Epo) may overcome limitations of single-agent therapy.
    • Novel fusion proteins offer potential for improved efficacy in treating hematological disorders.
    • This research paves the way for advanced HGF-based therapies.